According to biospectrumasia.com, Australian startup Lumonus, a leader in AI-powered radiation oncology workflow solutions, has successfully closed a A$25 million Series B financing round. The round was spearheaded by Aviron Investment Management, with continued support from Oncology Ventures.
This funding underscores the significant clinical adoption of Lumonus AI across health systems in the U.S., Australia, and Europe, where it is integrated into routine clinical care. To date, the platform has assisted clinicians in consulting and prescribing over 280,000 cancer treatments and has automated the creation of more than 75,000 treatment plans. This showcases its potential in optimizing oncology workflows and improving the consistency and efficiency of care.
The funds from this Series B round will be directed towards expanding Lumonus’ U.S. market presence, enhancing its flagship products, Lumonus AI Physician and Lumonus AI Dosimetry, and advancing clinical informatics capabilities. The company aims to broaden its collaborations with health systems to leverage real-world data, enhance quality measurement, improve operational performance, and deliver more personalized, data-driven cancer care.
The leadership team at Lumonus brings over a century of combined expertise from global cancer centers, reinforcing the company’s mission to empower oncology care teams and provide high-quality, efficient treatments.